Overview

• Apollo’s board has cleared a composite scheme to spin off its pharmacy and digital health units into Apollo Healthtech with a planned NSE and BSE listing in 18–21 months and an FY27 revenue target of Rs 25,000 crore.
• The new entity will be formed by merging Apollo Healthco Ltd and Keimed Pvt Ltd, while Apollo Hospitals will retain a 15% equity stake post-demerger.
• Shareholders of Apollo Hospitals will receive 195.2 shares of Apollo Healthtech for every 100 shares they hold in the parent company.
• Apollo Healthtech will house the Apollo 24/7 online platform, wholesale pharmaceutical distribution, offline pharmacies and telehealth services within an IOCC framework.
• Analysts at Citi and Morgan Stanley say the separation could unlock value in high-growth segments and help re-rate Apollo’s core hospital business.